https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-11-04 / Expert Opin Biol Ther 2024 Nov;24(11):1245-1259
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-11-04 / Expert Opin Biol Ther 2024 Nov;24(11):1245-12592024-11-04 00:00:002025-02-25 11:05:42The future of cellular therapy for the treatment of renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-08-11 / Int Immunopharmacol 2023 Oct;123:110722
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-08-11 / Int Immunopharmacol 2023 Oct;123:1107222023-08-11 00:00:002023-08-11 00:00:00Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-06-30 / Hum Vaccin Immunother 2023 Aug;19(2):2220629
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-06-30 / Hum Vaccin Immunother 2023 Aug;19(2):22206292023-06-30 00:00:002023-06-30 00:00:00A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-05-31 / Eur Urol Focus 2022 May;8(3):651-653
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-05-31 / Eur Urol Focus 2022 May;8(3):651-6532022-05-31 00:00:002022-05-31 00:00:00Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-262
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-2622020-01-27 00:00:002020-01-27 00:00:00Novel immunotherapy combinations for genitourinary cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-01 / Urol Ann 2019 Apr-Jun;11(2):119-125
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-01 / Urol Ann 2019 Apr-Jun;11(2):119-1252019-04-01 00:00:002019-04-01 00:00:00New treatment modalities with vaccine therapy in renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-277
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-2772018-05-30 00:00:002019-02-15 08:48:15Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-3512017-03-21 00:00:002017-03-21 00:00:00Current status of clinical trials assessing oncolytic virus therapy for urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-01 / Immunotherapy 2017 03;9(4):319-329
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-01 / Immunotherapy 2017 03;9(4):319-3292017-03-01 00:00:002019-02-15 08:48:14Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / BJU Int. 2016 10;118(4):506-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / BJU Int. 2016 10;118(4):506-142016-06-03 00:00:002019-02-15 08:52:00Recent advances in immuno-oncology and its application to urological cancers
